Wird geladen...
How recent advances in immunotherapy are changing the standard of care for patients with metastatic melanoma
In 2011, two therapies were approved for the treatment of metastatic melanoma: ipilimumab, an immunotherapeutic agent, and vemurafenib, a BRAF kinase inhibitor. These approvals were based on data from phase III trials, which showed that treatment with these agents produced substantial improvements i...
Gespeichert in:
| Veröffentlicht in: | Ann Oncol |
|---|---|
| 1. Verfasser: | |
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
Oxford University Press
2012
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6278954/ https://ncbi.nlm.nih.gov/pubmed/22918923 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/annonc/mds258 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|